A biotech company that studies psychedelics for alcohol addiction just made an unexpected pivot into the electric vehicle charging business.

Clearmind Medicine announced Friday it will acquire a 51 percent stake in Charging Robotics for 2.5 million dollars, marking one of the more unusual M&A moves of 2026. The deal pairs a NASDAQ-listed pharmaceutical developer with an Israeli startup building wireless charging systems for automated parking garages.

Closing is expected during the week of September 7, subject to specified conditions.

From Psychedelics to EV Infrastructure

Clearmind Medicine (NASDAQ: CMND) specializes in developing psychedelic-based treatments for alcohol use disorder. The company's pipeline includes synthetic compounds designed to reduce cravings without the hallucinogenic effects of traditional psychedelics.

Charging Robotics, by contrast, makes 10-kilowatt wireless charging pads that work with automated valet parking systems. The technology allows electric vehicles to park themselves over charging plates embedded in garage floors, eliminating the need for drivers to plug in manually.

The two businesses have nothing in common except timing: EV infrastructure is attracting massive investment as automakers race to meet emission deadlines, and Clearmind needs diversification as its clinical trials advance through the FDA approval gauntlet.

The Deal Structure

Clearmind will pay 2.5 million dollars for its 51 percent majority stake and extend a 1.5 million dollar loan to Charging Robotics at 4 percent annual interest. That loan gives Clearmind leverage while keeping the acquisition price low — a structure that protects the buyer if the EV charging market doesn't materialize as expected.

The lower purchase price also reflects reality: Charging Robotics is betting on a technology that's still unproven at scale. Wireless EV charging exists in demonstration projects and luxury developments, but it hasn't broken into mass-market parking garages or residential buildings.

Clearmind is essentially buying an option on the future of EV infrastructure, structured to limit downside if that future doesn't arrive.

Why A Biotech Buys EV Charging

Pharmaceutical startups face years of clinical trials, regulatory reviews, and capital-intensive development before generating revenue. Clearmind's most advanced compound won't reach patients for at least another 18 to 24 months, assuming FDA approval.

That timeline creates cash flow pressure. Acquiring a revenue-generating business — even one outside its core expertise — gives Clearmind a hedge against the inherent risk of drug development.

The move also reflects a broader trend: as venture capital dries up for speculative biotech, companies are looking for non-dilutive ways to diversify. An acquisition with seller financing (the 1.5 million dollar loan) preserves equity while adding a second business line.

The Bigger Bet on Automated Parking

Charging Robotics' technology only makes sense in fully automated parking environments, where vehicles park themselves without human intervention. That market is still nascent — most garages still require drivers to find spots and plug in manually.

But if autonomous valet parking becomes standard in urban buildings and airports, wireless charging becomes a competitive advantage. Developers can advertise "park and forget" systems where cars charge themselves overnight.

Several luxury residential towers in Miami and San Francisco already offer wireless charging as an amenity. Charging Robotics is betting that feature trickles down to commercial garages and office buildings as EV adoption accelerates.

What It Means for Clearmind

The deal won't move the needle on Clearmind's stock price — a 2.5 million dollar acquisition is tiny for a NASDAQ-listed company. But it signals that management sees risk in putting all its chips on psychedelic drug development.

If the FDA approves Clearmind's lead compound, the company could unload Charging Robotics to refocus on pharmaceuticals. If the drug fails, Clearmind has a fallback business in a high-growth sector.

It's hedging, not strategy. But for a biotech facing years of binary risk, hedging might be the smartest move available.